Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMiguel Martín, Noelia Jáñez Martínez, Frankie A. Holmes et al.|The Lancet Oncology|2017Cited by 594
Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional StudyLothar Bergmann, Christian Doehn, Peter J. Goebell et al.|Oncology Research and Treatment|2013Cited by 15
Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study.Peter J. Goebell, Lothar Bergmann, Ulrich Kube et al.|Journal of Clinical Oncology|2014Cited by 5
Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patientsAlexandra Samsen, Hartmut Juhl, Silvia von der Heyde et al.|Oncotarget|2018Cited by 4
Contents of Forthcoming Issues · ThemenvorschauCornelius Mensing, Hakan Karagöl, Albrecht Kretzschmar et al.|Oncology Research and Treatment|2009Cited by 1